TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dl-3-n-butylphthalide and Cerebrolysin Treatment in Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke within 12 hours for the first time before entry into the study~* National Institutes of Health Stroke Scale (NIHSS) score between 6 and 25~Exclusion Criteria:~* with lacunar infarction~* with cerebral hemorrhagic infarction~* with epilepsy or epileptic persons~* with history of neurological diseases~* with myocardial infarction,~* with renal and hepatic abnormalities~* with metabolic diseases~* with contraindications to antiplatelet treatments

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Dl-3-n-butylphthalide (Type: EXPERIMENTAL): Intravenous infusion of 25mg dl-3-n-butylphthalide b.i.d.for 10 days
- Cerebrolysin (Type: EXPERIMENTAL): Intravenous infusion of 30 ml cerebrolysin q.d. for 10 days
- Placebo (Type: PLACEBO_COMPARATOR): Intravenous infusion of 100 ml saline intravenous q.d. for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or nor pregnant or lactating female outpatients, 18 years of age or older.~* A clinical diagnosis of acute bacterial uncomplicated maxillary sinusitis as demonstrated by presence of the following signs and symptoms for a minimum duration of 7-10 days:~  1. Facial pain, pressure and/or tightness over one or both maxillary sinuses, and/or pain in one or both maxillary areas that worsens with movement or percussion, and~ 2. Presence of one or more of the following signs:~  i.purulent nasal discharge ii.purulent drainage in the posterior pharynx iii.purulent discharge from the maxillary sinus orifice~* A sinus X-ray (Water's view) confirming the clinical diagnosis of maxillary sinusitis. At least one of the following must be documented in one or both maxillary sinuses on radiologic examination:~  1. complete or partial opacification~ 2. an air/fluid level~Two or more of the following:~1. fever, as defined by temperature: \>38ºC~2. leukocytosis \[White Blood Cell (WBC) \>10,000/mm3 or \>15% band forms\], ECR;~3. headache,~4. nasal congestion and post nasal drainage.~Exclusion Criteria:~* Known or suspected hypersensitivity or intolerance or contraindications to Azithromycin, Amoxiclav according to LPDs, pregnant or lactating women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Azithromycin SR (Type: None): Acute Bacterial Maxillary Sinusitis
- Amoxiclav 1000 mg (Type: None): Acute Bacterial Maxillary Sinusitis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Carboplatin, and Oral Etoposide Followed by Weekly Paclitaxel in High Grade Neuroendocrine Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~To be included in this study, you must meet the following criteria:~* Metastatic poorly differentiated neuroendocrine carcinoma~* Unknown primary site~* Able to perform activities of daily living with minimal assistance~* Measurable or evaluable disease~* Adequate bone marrow, liver functions and kidney function~* No previous treatment with chemotherapy~* Understand the nature of this study and give written informed consent.~Exclusion Criteria:~You cannot participate in this study if any of the following apply to you:~* Age \< 18 years~* Previous malignancy within five years~* Women pregnant or lactating~* Recent history of cardiovascular disease~* Meningeal metastases~Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Thiamin Against Robust IBD Fatigue

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Inflammatory Bowel Disease~* Disease in remission~* Chronic fatigue~Exclusion Criteria:~* Co-morbidity that can explain fatigue~* Pregnancy~* Non-compliance to the study procedures~* Possible surgery in the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Thiamin (Type: ACTIVE_COMPARATOR): Oral thiamine: 600 - 1800 mg/day in 4 weeks. Dose is depending on gender and age. Tablet contains 300 mg Thiamine each.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo: same number of tablets as in the active comparator arm, in 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Ultrasound-Guided Infraclavicular Block and Ultrasound-Guided Axillary Block

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years or older~* American Society of Anesthesiologists Class 1 to 3~* Undergoing a surgery at the elbow, forearm, wrist or hand under regional anesthesia~Exclusion Criteria:~* Age less than 18 years~* Body mass index more than 40 kg/m2~* Weight less than 45 kg~* Patient refusal~* Contraindication to regional anesthesia (coagulopathy, local infection at the puncture site, systemic infection)~* Previous neurological deficit in the operated arm~* Severe renal or hepatic failure~* Prior surgery in the axillary or infraclavicular area~* Pregnancy or breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ultrasound-guided infraclavicular block (Type: ACTIVE_COMPARATOR): Ultrasound-guided single injection infraclavicular block
- Ultrasound-guided axillary block (Type: ACTIVE_COMPARATOR): Ultrasound-guided double injection axillary block

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years or older.~2. Diagnosis of RA based on the 1987 American College of Rheumatology revised criteria~3. Current continuous treatment with either etanercept, adalimumab, or infliximab for a minimum of 6 months and maximum of 24 months.~Exclusion Criteria:~1. Treatment with biosimilar or investigational etanercept, adalimumab, or infliximab within past 6 months.~2. Treatment with any other investigational drugs within past 3 months or five half lives of the drug, whichever is longer.~3. Any medical condition that would interfere with rheumatoid arthritis evaluation or other study assessments (eg, fibromyalgia, lupus).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- etanercept (Type: None): Participants currently receiving etanercept treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
- adalimumab (Type: None): Participants currently receiving adalimumab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.
- infliximab (Type: None): Participants currently receiving infliximab treatment in a clinical setting for a minimum of 6 months and maximum of 24 months prior to study assessment visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Cone-beam CT for Percutaneous Nephrolithotomy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients \>18 years old~2. Scheduled for percutaneous nephrolithotomy with stone fragmentation (laser/ultrasonic/mechanical)~3. For the prospective intervention arm, willingness to consent to participate in the study~Exclusion Criteria:~1. Patients whose habitus does not allow for the use of the cone beam CT machine~2. Patients whose stones only reside within the mid or distal ureter(s) and thus would not be easily imaged with cone beam CT~3. Patients who have had lithotripsy on their renal unit within the prior 90 days~4. Pregnant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention arm (Type: EXPERIMENTAL): This arm will receive cone beam CT to perform an abdomen-pelvis CT scan immediately following initial percutaneous nephrolithotomy, before the patient emerges from general anesthesia, to allow the surgeon to determine whether additional work is needed or whether the procedure can be concluded without requiring further imaging or future interventions.
- Retrospective arm (Type: NO_INTERVENTION): This arm will contain a retrospective cohort of patients who underwent surgery prior to the enrollment of the intervention arm. These patients received the standard of care, namely helical CT postoperative day one.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed metastatic, measurable cancer or resected high risk Stage III/IV; resected Stage II, III, or IV non-small cell lung cancer or esophageal cancer who have declined, failed, or completed standard therapy; tumor expression of NY-ESO-1 or LAGE-1 antigen; HLA-A2 positive; Karnofsky performance status greater than or equal to 60%; hematology and biochemistry laboratory results within the limits normally expected for the patient population; age greater than or equal to 18.~Exclusion Criteria:~* Clinically significant heart disease; other serious illnesses; patients with serious intercurrent illness, requiring hospitalization; patients taking immunosuppressive drugs; autoimmune disease; known HIV positivity; other active malignancy within 1 year prior to entry into the study; participation in chemotherapy, radiation therapy, or any other clinical trial involving another investigational agent within 4 weeks prior to enrollment; pregnancy or breastfeeding; women of childbearing potential: refusal or inability to use effective means of contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with Cancer Expressing NY-ESO-1 or LAGE-1 Antigen. (Type: EXPERIMENTAL): NY-ESO-1b peptide, 100 μg mixed with 1 mg CpG 7909 and 0.5mL of Montanide® ISA-51 was administered to patients with cancer expressing NY-ESO-1 or LAGE-1 antigen. The injections were given subcutaneously beginning on week 1 and repeated every three weeks for 4 injections total. There was a 3 week follow-up period after the last injection. In the absence of toxicity and progressive disease (PD), a second cycle was offered to patients who received 4 vaccinations.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anti-Inflammatory Effects of Mango Polyphenolics in Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ages 18-79 years (see Protection of Human Subjects)~* Treated with mesalamine or any mesalamine derivate, e.g.Asacol, Apriso, Asacol, Canasa, Lialda, Pentasa, Rowasa orally or rectally as standard of clinical care in the treatment of their symptoms for Inflammatory bowel disease~* Treated using biologic immune-modulators including but not limited to: Infliximab, Adalimumab, Certolizumab, Natalizumab, azathioprine.~* Additionally, patients may be on steroids (prednisone 10mg, budesonide 9mg)~* Subjects must have been on a stable drug-regiment for at least 3 weeks before study begin.~Exclusion Criteria:~* history of acute cardiac event, stroke, or cancer, within the last 6 months,~* recurrent hospitalizations,~* drug treatment of any of the listed conditions within the last 6 months,~* abuse of alcohol or substance within the last 6 months,~* currently smoking more than 1 pack/week,~* seizures,~* liver or renal dysfunction,~* pregnancy or lactation,~* allergy against mangos,~* hepatitis B, C, or HIV,~* regular exercise (\>60 minutes, ≥ 5 times/wk), due to association of antioxidant and anti-inflammatory effects and moderate exercise.~* known lactose intolerance, gluten sensitivity, or celiac disease~* Patients that have upcoming Inflammatory bowel disease-related surgery and Inflammatory bowel disease -related intestinal stricture will also be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 72 Years
- Healthy Volunteers: f

Study Arms:
- Mango (Type: EXPERIMENTAL): Mango polyphenolics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet criteria for attention deficit hyperactivity disorder~* Have voluntarily signed an informed consent form~* Are between 18 and 60 years of age~* Will use contraceptive methods during the study~* Women must not be pregnant or breast-feeding~* Must be in generally good health~* Are fluent in English~Exclusion Criteria:~* They have a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder or mental retardation~* They have a current diagnosis of major depressive episode, generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) or have a clinically significant sleep disorder requiring treatment~* They require ongoing treatment or expected treatment with any psychotropic medication, including anxiolytics, antipsychotics, anticonvulsants, antidepressants or mood stabilizers~* They failed to respond to two or more adequate trials of FDA-approved ADHD medication~* They have violent, homicidal or suicidal ideation~* They have a significant history of medical diagnoses, seizure disorder, Tourette's syndrome or a central nervous system (CNS) disease, excluding ADHD~* They have a urine drug screen that is positive for alcohol or drugs of abuse~* They have a history of substance or alcohol disorder (abuse/dependence) during the last 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Years

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects \>15months to \<18years in good health, available for entire study period and reachable by phone, parents/legal guardian able and willing to complete all study procedures, written documentation from health professional showing prior vaccination with Prevnar (except for group 4).~Group 4 only:~* Negative urine pregnancy test for female subjects who are menstruating.~Exclusion Criteria:~* Previous reaction or contra-indication to pneumococcal vaccine or vaccine related component , bleeding diathesis, received blood transfusion or blood related products, immune deficiency,congenital malformation.~Group 4 only:~* Previous vaccination with Prevnar or any other pneumococcal vaccine.~* Pregnant or breastfeeding adolescent females.

- Gender: ALL
- Minimum Age: 15 Months
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Single (Type: EXPERIMENTAL): Open label

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Treatment of Glabellar Lines: Efficacy and Safety Study I

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Aged ≥ 18 years or older at time of screening~* Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on FWS) as determined by in-clinic assessments by both the investigator and the subject(where: 0= 'none', 1= 'mild', 2= 'moderate', 3= 'severe').~  * 18 years of age~Exclusion Criteria:~* Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator's discretion) that might interfere with neuromuscular function or contraindicate botulinum toxin therapy.~* Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to screening, or any planned treatment with botulinum toxin of any serotype for any reason during the trial (other than the investigational treatment).~* Active skin disease/infection or irritation at the treatment area~* Pregnant, breastfeeding or planning to become pregnant during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Botulinum toxin A (Type: EXPERIMENTAL): Botulinum Toxin A (Clostridium botulinum toxin type A) will be administered in double blind fashion in cycle 1. 20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo will be administered in double blind fashion in cycle 1. divided in five 0.1 mL i.m. injections into the glabellar area.
- Botulinum toxin A Open Label Extension Arm (Type: EXPERIMENTAL): Open Label Extension Arm where all Subjects from Arm 1 and 2 can receive Experimental Treatment in up to 3 treatment cycles.~20 Units will be administered (divided in five 0.1 mL i.m. injections) into the glabellar area.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete